GlassScriptPhysician profile
Jeffrey Kartchner
NPI 1760910483
$1,823.75
in general payments reported to CMS, 2019-2025
17 companies · $271 in 2025
The $271 reported for 2025 was less than what a typical Ophthalmology provider received nationally (typical 2025 total: $384).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $435 · 2020: $15.85 · 2021: $188 · 2022: $352 · 2023: $264 · 2024: $298 · 2025: $271.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $815 · Education: $17.84.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $814.91 |
| Education | $17.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Johnson & Johnson Surgical Vision, INC. | $296.79 | 2021-2023 | Tecnis Simplicity, Veritas Vision System |
| Allergan, INC. | $239.31 | 2019 | |
| Alcon Vision LLC | $236.89 | 2019-2025 | Rocklatan, Tryptyr |
| Glaukos Corporation | $215.26 | 2019-2023 | Istent Inject Trabecular Micro-Bypass System, Iaccess Precision Blade, Istent Inject Trabecular Micro-Bypass System |
| Sight Sciences, INC. | $156.83 | 2024 | Omni Surgical System |
| Bausch & Lomb Americas INC. | $153.04 | 2023-2025 | Xiidra, Miebo |
| Alimera Sciences, INC. | $94.40 | 2019 | |
| Genentech USA, INC. | $75.54 | 2019 | |
| Novartis Pharmaceuticals Corporation | $72.37 | 2022-2023 | |
| Rxsight INC | $61.77 | 2022-2025 | Rxsight Contact Lens, Light Adjustable Lens (Lal), Rxsight Injector Cartridge |
| Amgen INC. | $53.58 | 2025 | Tepezza |
| Oyster Point Pharma, INC. | $48.10 | 2023-2025 | Tyrvaya, Ryzumvi, Ryzumvi |
| Tarsus Pharmaceuticals, INC. | $40.39 | 2025 | Xdemvy |
| Abbvie INC. | $28.46 | 2024 | |
| Dompe US, INC. | $21.11 | 2025 | Oxervate |
Show all 17 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Thea Pharma INC. | $15.46 | 2022 | |
| Ocular Therapeutix, INC. | $14.45 | 2024 | Dextenza |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Kartchner listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.